Skin Cancer

Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

By

Since next-generation sequencing reflex testing has been implemented at Case Western Reserve University School of Medicine, several cases of potentially actionable mutations have been identified that would not have been caught by PCR alone.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Indoor Tanning and Cancer

Indoor Tanning and Cancer

By

All meta-analyses conducted to date show a significant association between indoor tanning use and an increased risk of melanoma or non-melanoma skin cancers.

FDA Approves Encorafenib Plus Binimetinib for <i>BRAF V600E, V600K</i> Mutation-Positive Melanoma

FDA Approves Encorafenib Plus Binimetinib for BRAF V600E, V600K Mutation-Positive Melanoma

By

The FDA based their approval on findings from the phase 3 COLUMBUS study, in which researchers randomly assigned patients with BRAF V600-mutant melanoma to receive encorafenib plus binimetinib, encorafenib, or vemurafenib.

Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

By

Novel targets in the treatment of melanoma was a hot topic of discussion during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Radiation and Immunotherapy Show Possible Survival Advantage in Melanoma-Related Brain Metastases

Radiation and Immunotherapy Show Possible Survival Advantage in Melanoma-Related Brain Metastases

By

Results from a small study show that PD-1 inhibitors could work synergistically with radiosurgery to promote slightly longer survival times.

FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy for Melanoma

FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy for Melanoma

By

If approved, the new indication could mean pembrolizumab could be used for patients with melanoma.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

By

Patient age should play a role in drug development strategies for melanoma, researchers of a new study say.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Two-Year Data from BAVENCIO (avelumab) in Metastatic Merkel Cell Carcinoma

Two-Year Data from BAVENCIO (avelumab) in Metastatic Merkel Cell Carcinoma

Paul Nghiem, MD, PhD, discusses his findings at the ASCO 2018 meeting.

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

By

Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

By

When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

By

Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.

Encorafenib Plus Binimetinib for Metastatic Melanoma

Encorafenib Plus Binimetinib for Metastatic Melanoma

Victor Sandor, MD, discusses the treatment combination at the ASCO 2018 meeting in Chicago.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Marital Status Predicts Melanoma Stage at Diagnosis—But Why?

Marital Status Predicts Melanoma Stage at Diagnosis—But Why?

By

Married people are more likely than unmarried, divorced, or widowed patients to be diagnosed with skin cancer at early, more readily-treatable stages of disease.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

By

The FDA based its approval on the results of the phase 3 COMBI-AD study.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

The Benefits of Adjuvant Immunotherapy in Melanoma

The Benefits of Adjuvant Immunotherapy in Melanoma

By

KEYNOTE-054 may show whether some patients with resected disease can forego adjuvant therapy.

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

By

Sentinel nodes were accurately identified in all 30 patients who underwent WLE.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Late-Onset Toxicity Possible With Immunotherapy

Late-Onset Toxicity Possible With Immunotherapy

By

Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

By

Improvement in RFS was seen regardless of PD-L1 status.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs